AnGes, Inc.
Announcement of Grant Award to Support Development of Subcutaneous Formulation of Co-developed Tie2 Receptor Agonist (AV-001)
Announced receipt of up to 280,347 Canadian dollars in funding and advisory services from NRC IRAP to support development of a subcutaneous formulation of co-developed AV-001. Introduction of subcutaneous administration is expected to expand dosing options and enable earlier intervention.
Key Figures
- Key figure 1: Up to 280,347 Canadian dollars (approx. 31,500 thousand yen)
- Key figure 2: Target drug AV-001 (Pegevongitide)
- Key figure 3: Period: Unknown (funding provided by NRC IRAP)
AI要約
News Summary
AnGes, Inc. announced that it will receive up to 280,347 Canadian dollars in R&D funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support development of a subcutaneous formulation of the Tie2 receptor agonist AV-001, being co-developed with Vasomune Therapeutics, Inc. The introduction of subcutaneous administration is positioned as an important step to broaden administration routes and timing options and to enable earlier intervention.
Background and Significance
Adding subcutaneous administration could diversify dosing methods in addition to the current intravenous administration and may expand the applicability of treatments targeting vascular endothelial injury and vascular leakage. Utilization is anticipated in both civilian and military contexts, strengthening prevention and response through stabilization of the vascular endothelium via early intervention. Vasomune is advancing development of this therapeutic with dual-use applications in mind.
AnGes, Inc.
Company overview · Stock price · Financial data · All IR
